MX2020012989A - Agente terapeutico para la fibrosis. - Google Patents
Agente terapeutico para la fibrosis.Info
- Publication number
- MX2020012989A MX2020012989A MX2020012989A MX2020012989A MX2020012989A MX 2020012989 A MX2020012989 A MX 2020012989A MX 2020012989 A MX2020012989 A MX 2020012989A MX 2020012989 A MX2020012989 A MX 2020012989A MX 2020012989 A MX2020012989 A MX 2020012989A
- Authority
- MX
- Mexico
- Prior art keywords
- fibrosis
- therapeutic agent
- amino
- therapeutic
- thioxomethyl
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title abstract 4
- 230000004761 fibrosis Effects 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 3
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- ORRNXRYWGDUDOG-UHFFFAOYSA-N 4-[2-fluoro-4-[(2-phenylacetyl)carbamothioylamino]phenoxy]-7-methoxy-n-methylquinoline-6-carboxamide Chemical compound C1=CN=C2C=C(OC)C(C(=O)NC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=S)NC(=O)CC1=CC=CC=C1 ORRNXRYWGDUDOG-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
Abstract
Se proveen un agente terapéutico y una composición farmacéutica que exhiben excelente efecto profiláctico o terapéutico contra la fibrosis o los síntomas asociados con la fibrosis; este agente terapéutico para la fibrosis contiene 4-[2-fluoro-4-[[[(2-fenilace til)amino]tioxometil]amino]-fenoxi]-7-metoxi-N-metil-6-quinolinca rboxamida o una sal de la misma como un ingrediente activo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015127788 | 2015-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012989A true MX2020012989A (es) | 2021-02-16 |
Family
ID=57585165
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016774A MX381792B (es) | 2015-06-25 | 2016-06-24 | Agente terapéutico para la fibrosis. |
| MX2020012989A MX2020012989A (es) | 2015-06-25 | 2017-12-19 | Agente terapeutico para la fibrosis. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016774A MX381792B (es) | 2015-06-25 | 2016-06-24 | Agente terapéutico para la fibrosis. |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10449189B2 (es) |
| EP (2) | EP3315131B1 (es) |
| JP (3) | JP6974167B2 (es) |
| KR (1) | KR102647942B1 (es) |
| CN (2) | CN107708697B (es) |
| AU (1) | AU2016284531B2 (es) |
| BR (1) | BR112017028137B1 (es) |
| CA (1) | CA2990791A1 (es) |
| DK (1) | DK3315131T3 (es) |
| ES (1) | ES2928684T3 (es) |
| HU (1) | HUE060732T2 (es) |
| MA (1) | MA42266A (es) |
| MX (2) | MX381792B (es) |
| MY (1) | MY191219A (es) |
| PH (1) | PH12017502322B1 (es) |
| PL (1) | PL3315131T3 (es) |
| PT (1) | PT3315131T (es) |
| RU (1) | RU2729630C2 (es) |
| SG (2) | SG11201709260TA (es) |
| WO (1) | WO2016208744A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007139608A1 (en) | 2006-03-14 | 2007-12-06 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| US12152246B2 (en) | 2006-03-14 | 2024-11-26 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| DK3583943T3 (da) | 2017-02-15 | 2024-10-14 | Taiho Pharmaceutical Co Ltd | Farmaceutisk sammensætning |
| US12280045B2 (en) | 2017-09-08 | 2025-04-22 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent and antitumor effect potentiator |
| WO2020059744A1 (ja) | 2018-09-18 | 2020-03-26 | 大鵬薬品工業株式会社 | アシルチオウレア化合物とアビラテロンの併用療法 |
| TWI872203B (zh) | 2020-02-14 | 2025-02-11 | 日商大鵬藥品工業股份有限公司 | 醯基硫脲化合物的製造方法 |
| CN115177636A (zh) * | 2022-07-18 | 2022-10-14 | 陕西科美致尚生物科技有限公司 | 一种用于治疗前列腺钙化的组合物及其制备方法与应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2327382C (en) | 1998-04-28 | 2012-12-18 | Toshikazu Nakamura | Neovascularization inhibitors |
| JP2003238592A (ja) | 2001-12-13 | 2003-08-27 | Japan Tobacco Inc | 組織及び血管の再生のための医薬及びその方法 |
| WO2007005668A2 (en) | 2005-06-30 | 2007-01-11 | Amgen Inc. | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer |
| ZA200804681B (en) * | 2005-11-30 | 2009-11-25 | Vertex Pharma Inc | Inhibitors of C-Met and uses thereof |
| EP1963329B1 (en) | 2005-11-30 | 2013-01-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| MX2009008531A (es) | 2007-02-16 | 2009-08-26 | Amgen Inc | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. |
| KR20100089090A (ko) | 2007-10-25 | 2010-08-11 | 아스트라제네카 아베 | 세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체 |
| SI2287155T1 (sl) * | 2008-04-10 | 2013-10-30 | Taiho Pharmaceutical Co., Ltd. | Aciltiosečninska spojina ali njena sol in njena uporaba |
| UY32049A (es) * | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| BR112012019302B1 (pt) | 2010-02-03 | 2022-06-21 | Incyte Holdings Corporation | Imidazo[1,2-b] [1,2,4]triazinas como inibidores de c-met, composição que as compreende e métodos in vitro de inibir a atividade de c-met cinase, de inibir a via de sinalização da hgf/c-met cinase em uma célula e de inibir a atividade proliferativa de uma célula |
| KR101871436B1 (ko) | 2010-05-17 | 2018-06-27 | 인코젠 쎄라퓨틱스 프라이빗 리미티드 | 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3ｈ-이미다조[4,5-ｂ]피리딘 및 3,5- 디치환 -3ｈ-[1,2,3]트리아졸로[4,5-ｂ] 피리딘 화합물 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| RU2494470C1 (ru) * | 2012-04-04 | 2013-09-27 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") | Способ лечения фиброза легких |
| US9149471B2 (en) | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
-
2016
- 2016-06-24 PL PL16814513.4T patent/PL3315131T3/pl unknown
- 2016-06-24 BR BR112017028137-6A patent/BR112017028137B1/pt active IP Right Grant
- 2016-06-24 DK DK16814513.4T patent/DK3315131T3/da active
- 2016-06-24 MX MX2017016774A patent/MX381792B/es unknown
- 2016-06-24 RU RU2017145271A patent/RU2729630C2/ru active
- 2016-06-24 CN CN201680037175.7A patent/CN107708697B/zh active Active
- 2016-06-24 EP EP16814513.4A patent/EP3315131B1/en active Active
- 2016-06-24 SG SG11201709260TA patent/SG11201709260TA/en unknown
- 2016-06-24 PH PH1/2017/502322A patent/PH12017502322B1/en unknown
- 2016-06-24 CA CA2990791A patent/CA2990791A1/en active Pending
- 2016-06-24 HU HUE16814513A patent/HUE060732T2/hu unknown
- 2016-06-24 US US15/574,060 patent/US10449189B2/en active Active
- 2016-06-24 KR KR1020177033481A patent/KR102647942B1/ko active Active
- 2016-06-24 ES ES16814513T patent/ES2928684T3/es active Active
- 2016-06-24 SG SG10201912684TA patent/SG10201912684TA/en unknown
- 2016-06-24 MA MA042266A patent/MA42266A/fr unknown
- 2016-06-24 JP JP2017525457A patent/JP6974167B2/ja active Active
- 2016-06-24 CN CN202110067291.6A patent/CN112716952A/zh active Pending
- 2016-06-24 MY MYPI2017704204A patent/MY191219A/en unknown
- 2016-06-24 EP EP21205221.1A patent/EP3973962A1/en not_active Withdrawn
- 2016-06-24 PT PT168145134T patent/PT3315131T/pt unknown
- 2016-06-24 WO PCT/JP2016/068902 patent/WO2016208744A1/ja not_active Ceased
- 2016-06-24 AU AU2016284531A patent/AU2016284531B2/en active Active
-
2017
- 2017-12-19 MX MX2020012989A patent/MX2020012989A/es unknown
-
2019
- 2019-09-17 US US16/573,362 patent/US10695340B2/en active Active
-
2020
- 2020-06-02 US US16/889,870 patent/US11191759B2/en active Active
-
2021
- 2021-10-29 US US17/513,946 patent/US11690838B2/en active Active
- 2021-11-04 JP JP2021180108A patent/JP7258985B2/ja active Active
-
2023
- 2023-04-05 JP JP2023061284A patent/JP7498827B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020012989A (es) | Agente terapeutico para la fibrosis. | |
| PH12020550792A1 (en) | Compounds useful for inhibiting cdk7 | |
| MX2016016593A (es) | Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos. | |
| PH12018502109A1 (en) | Medicine obtained by combining fxr agonist and arb | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| WO2015070224A3 (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| EP4527467A3 (en) | Pharmaceutical formulations | |
| PH12017501084A1 (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| PH12018500358A1 (en) | Compounds for use in an antibacterial applications | |
| MY183068A (en) | Pharmaceutical formulation comprising antibody | |
| EP4342461A3 (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| MX2019008338A (es) | Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco. | |
| WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
| WO2016006975A3 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
| PH12020500510A1 (en) | Prophylactic and/or therapeutic agent for diseases involving ido expression | |
| WO2014145126A3 (en) | Methods of treating dyskinesia and related disorders | |
| PH12018501758A1 (en) | Oritavancin formulations | |
| PH12018501991A1 (en) | Pharmaceutical composition for use in treating fibrosis | |
| PH12018500579A1 (en) | Fungal keratitis prophylactic or therapeutic agent | |
| EP3881845A3 (en) | Combination of trazodone and gabapentin for the treatment of pain | |
| WO2017210527A8 (en) | Autotaxin inhibitors | |
| TR201721065A2 (tr) | Deksmedetomi̇di̇n i̇çeren li̇yofi̇li̇ze farmasöti̇k formülasyonlar | |
| ZA201803722B (en) | Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof |